Last updated date
ABOUT THIS STUDY
This investigation will utilize a systematic determination of anti-FVIII antibody specificity
in PTPs (> 50 ED) with hemophilia A who have developed inhibitors in response to treatment
with any FVIII product(s). A group of patients with hemophilia A, who have no evidence of
current or prior FVIII inhibitor will be included for comparison. The objective of this study
is to describe the patterns of antibodies and associated epitopes in the study population.
FOR MORE INFORMATION
Contact a representative by phone, email, or visiting the study website. Please see the references below:
By phone
Pfizer Clinical Trials Contact Center
1-800-718-1021
Eligibility Criteria
condition
The disease, disorder, syndrome, illness, or injury that is being studied.
Hemophilia A
Sex
Females and Males
Age
Pediatric Trials: 0-17 Years
Adult Trials: 18+ Years
Adult Trials: 18+ Years
0 +
Inclusion Criteria
The factors, or reasons, that allow a person to participate in a clinical study.
Show details
· Patients with moderate or severe congenital hemophilia A, a current FVIII inhibitor, who have taken at least two different FVIII products during their lifetime.
Exclusion Criteria
The factors, or reasons, that prevent a person from participating in a clinical study.
Show details
- Patients who have had an inhibitor prior to their current inhibitor.
- Patients with immune disorders.
NEED INFO?
Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center Representative
TRY A NEW SEARCH
Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your city or zip code to find studies near you.
Based on your search, you may also be interested in
Hemophilia AMoroctocog Alfa (AF-CC) for Prophylaxis and Treatment of Bleeding Episodes in Previously Treated Hemophilia A Patients
NCT04396639
- Surat, Gujarat
- Mumbai, Maharashtra
- Pune, Maharashtra
- Pune, Maharashtra
- Ludhiana, Punjab
Male
12 Years+
years
MULTIPLE SITES
Hemophilia AStudy to Evaluate the Efficacy and Safety of PF-07055480 in Moderately Severe to Severe Hemophilia A Adults
NCT04370054
- Seattle, Washington
- Seattle, Washington
Male
18 Years+
years
MULTIPLE SITES
Hemophilia AStudy Evaluating The Efficacy And Safety Of Xyntha In Children Less Than 6 Years Of Age
NCT00759655
Male
0+
years
MULTIPLE SITES
Hemophilia AStudy Evaluating B-Domain Deleted Recombinant Factor VIII (BDDrFVIII, ReFacto AF) in Patients With Hemophilia A Undergoing Elective Major Surgery
NCT00243659
- LaJolla, California
- Detroit, Michigan
- Detroit, Michigan
- Chapel Hill, North Carolina
- Hershey, Pennsylvania
- Pittsburg, Pennsylvania
- Houston, Texas
- Charlottesville, Virginia
- Perth,
- Vienna,
- Budapest,
- Auckland,
- Chirstchurch,
- Warsawa,
- Bucurest,
- Malmö,
- Stockholm,
Male
12 Years+
years
MULTIPLE SITES
Advanced Information
| Descriptive Information | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Brief Title ICMJE | Study Evaluating Inhibitor Specificity in Hemophilia A | ||||||||||||||||||
| Official Title ICMJE | A Multicenter Study to Describe the Immunogenic Epitope(s) of Factor VIII in Previously Treated Patients With Congenital Hemophilia A Who Develop De Novo Factor VIII Inhibitors While Receiving Factor VIII Infusion Therapy. | ||||||||||||||||||
| Brief Summary | This investigation will utilize a systematic determination of anti-FVIII antibody specificity in PTPs (> 50 ED) with hemophilia A who have developed inhibitors in response to treatment with any FVIII product(s). A group of patients with hemophilia A, who have no evidence of current or prior FVIII inhibitor will be included for comparison. The objective of this study is to describe the patterns of antibodies and associated epitopes in the study population. | ||||||||||||||||||
| Detailed Description | Not Provided | ||||||||||||||||||
| Study Type ICMJE | Interventional | ||||||||||||||||||
| Study Phase ICMJE | Phase 4 | ||||||||||||||||||
| Study Design ICMJE | Allocation: Non-Randomized Intervention Model: Parallel Assignment Masking: None (Open Label) Primary Purpose: Diagnostic | ||||||||||||||||||
| Condition ICMJE | Hemophilia A | ||||||||||||||||||
| Intervention ICMJE | Procedure: single blood draw | ||||||||||||||||||
| Study Arms ICMJE | Not Provided | ||||||||||||||||||
| Publications * | Not Provided | ||||||||||||||||||
* Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline. | |||||||||||||||||||
| Recruitment Information | |||||||||||||||||||
| Recruitment Status ICMJE | Withdrawn | ||||||||||||||||||
| Actual Enrollment ICMJE | 0 | ||||||||||||||||||
| Original Enrollment ICMJE | 18 | ||||||||||||||||||
| Actual Study Completion Date ICMJE | October 2007 | ||||||||||||||||||
| Primary Completion Date | Not Provided | ||||||||||||||||||
| Eligibility Criteria ICMJE | Inclusion Criteria: · Patients with moderate or severe congenital hemophilia A, a current FVIII inhibitor, who have taken at least two different FVIII products during their lifetime. Exclusion Criteria:
| ||||||||||||||||||
| Sex/Gender ICMJE |
| ||||||||||||||||||
| Ages ICMJE | Child, Adult, Older Adult | ||||||||||||||||||
| Accepts Healthy Volunteers ICMJE | No | ||||||||||||||||||
| Contacts ICMJE | Contact information is only displayed when the study is recruiting subjects | ||||||||||||||||||
| Listed Location Countries ICMJE | Belgium, France, Germany, Italy, Spain, United Kingdom, United States | ||||||||||||||||||
| Removed Location Countries | |||||||||||||||||||
| Administrative Information | |||||||||||||||||||
| NCT Number ICMJE | NCT00151385 | ||||||||||||||||||
| Other Study ID Numbers ICMJE | 3082A-101342 | ||||||||||||||||||
| Has Data Monitoring Committee | Not Provided | ||||||||||||||||||
| U.S. FDA-regulated Product | Not Provided | ||||||||||||||||||
| IPD Sharing Statement ICMJE | Not Provided | ||||||||||||||||||
| Responsible Party | Not Provided | ||||||||||||||||||
| Study Sponsor ICMJE | Wyeth is now a wholly owned subsidiary of Pfizer | ||||||||||||||||||
| Collaborators ICMJE | Not Provided | ||||||||||||||||||
| Investigators ICMJE |
| ||||||||||||||||||
| PRS Account | Wyeth is now a wholly owned subsidiary of Pfizer | ||||||||||||||||||
| Verification Date | June 2012 | ||||||||||||||||||
ICMJE Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP | |||||||||||||||||||